Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised, Double-blind, Placebo-controlled Phase III Study of APD421 (Amisulpride for IV Injection) as Combination Prophylaxis Against Post-operative Nausea and Vomiting in High-risk Patients

NCT02337062 is registered in ClinicalTrials.gov with Acacia Pharma Ltd as lead sponsor.

NCT NCT02337062
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02337062 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised, Double-blind, Placebo-controlled Phase III Study of APD421 (Amisulpride for IV Injection) as Combination Prophylaxis Against Post-operative Nausea and Vomiting in High-risk Patients
Lead sponsor
Acacia Pharma Ltd
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2015
Completion date
September 30, 2015
Enrollment
1,147 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

ponv